ArticleThe oncologist2026

Incidence and risk factors for pneumonitis in urothelial carcinoma treated with enfortumab vedotin plus pembrolizumab: retrospective study.

Luis Angel Diaz Tejada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.